Newsmeme!
Discover News you didn't know existed
Dear Dr. Donohue: You disappoint me beyond belief. I have sent the same letter four times and still can't get a response. My problem is heart failure. My condition is apparently deteriorating, as my most recent echocardiogram showed an ejection fraction of 20. A year and a half ago, it was 30. Attached is the copy of my original letter.
DEAR DR. DONOHUE: You disappoint me beyond belief. I have sent the same letter four times and still can't get a response. My problem is heart failure. My condition is apparently deteriorating, as my most recent echocardiogram showed an ejection fraction...
I was impressed a few weeks ago when volunteers, helped by community donations, painted over the graffiti, which “decorated” the north wall of the strip mall on the north end of Main Street. Great job folks! I drive by that area every day and it was like magic.
The National Institute for Health and Clinical Excellence (NICE) today announced that, following GlaxoSmithKline’s (GSK) appeal, it will reconsider the submission for Tyverb (lapatinib), a treatment for an aggressive form of advanced breast cancer (ErbB2-positive).1 GSK is pleased that NICE’s appeal panel agreed that the draft negative guidance should be reviewed, providing fresh hope for up to ...
Even though it may sound like it, heart failure does not necessarily mean that the heart has failed. Heart failure is a serious condition in which the heart is not pumping blood around the body efficiently. The patient's left side, right side, or even both sides of the body can be affected. Symptoms will depend on which side is affected and how severe the heart failure is - symptoms can be severe.
Many doctors don't provide the right treatments, triggering unnecessary hospitalizations—even deaths.
Cardiac MR module expands the clinical value of the Ziostation® Thin-Client Advanced Visualization System
Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular ...
Sanofi-aventis announced recently that the U.S. Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets.
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |